The FDA described two potential options for mandating pre-paid mail-back envelopes under the opioid REMS in a Federal Register notice. • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
